摘要
目的观察比较希罗达节拍化疗与传统疗法联合吉西他滨治疗蒽环类及紫杉类治疗失败的晚期乳腺癌的疗效与毒副反应。方法将接受蒽环类及紫杉类药物治疗失败的33例晚期乳腺癌癌患者随机分成A、B两组,A组为节拍化疗组,B组为传统化疗组。A组17例,治疗方案:吉西他滨1000mg/m2,静脉滴注30min,d1、d8;希罗达用量为1000mg/d,分两次于早晚餐后30min口服,d1～d21;B组16例,治疗方案:吉西他滨的用量、用法与A组相同;希罗达2500mg/m2,分两次于早晚餐后30min口服,d1～d14。每21d重复一次,至少两个周期评价疗效。结果 33例患者均可评价疗效,其中A组CR0例,PR8例,SD5例,PD4例;B组CR1例,PR7例,SD4例,PD4例。总有效率(CR+PR)节拍化疗组为47.06%,传统化疗组为50.00%。临床受益率(CR+PR+SD)节拍化疗组为76.47%,传统化疗组为75.00%。A、B两组间疗效差异无统计学意义(P>0.05)。结论希罗达节拍化疗与传统疗法联合吉西他滨治疗蒽环类及紫杉类治疗失败的晚期乳腺癌疗效相当,毒副反应均可耐受,但前者毒副反应较后者低且更有药物经济学优势,值得临床进一步研究。
Objective To compared the effects and side effects ofxeloda metronomic chemotherapy with traditional chemotherapy combined with gemcitabine for patients with advanced breast cancer failed to anthracycline and taxane-based chemotherapy. Methods 33 cases patients with advanced breast cancer failed to anthracyeline and tax- ane-based chemotherapy were randomly divided into group A and group B. 17 cases in group A were treated with xeloda metronomic chemotherapy, and 16 cases in group B with traditional chemotherapy combined with gemcitabine. Therapeutic regimen： group A： gemcitabine （1 000 mg/m2） IV drop 30 rain, on days 1, 8; xeloda 500 mg, P.O. after meal 30min Bid, on day 1-21; group B： the usage of gemcitabine was the same with that in group A. Xeloda 1 250 mg/ ms, P.O. after meal 30 min Bid, on day 1-14. The treatments were repeated once every 21 days. The assessment of ef- fect was performed at least once every two cycles. Results The therapeutic effect in all the patients were assessed. In group A： CR 0 case, PR 8 cases, SD 4 cases, PD 5 cases, and in group B： CR 1 case, PR 7 cases, SD 4 cases, PD 4 cases. The total effective rate （CR＋PR） of group A and group B were 47.06% and 50.00% respectively. The clinical rational rate （CR＋PR＋SD）of group A and group B were 76.47% and 75.00% respectively. There were no statistical differences between the two groups. Conclusion Compared with traditional chemotherapy combined with gemcitabine, there is no difference of xeloda metronomic chemotherapy for patients with advanced breast cancer failed to anthracycline and taxane-based chemotherapy.
出处
《海南医学》
CAS
2011年第17期12-15,共4页
Hainan Medical Journal
